SELLAS Life Sciences Group, Inc. (SLS) Revenue, Earnings & Financial Statements
$19.15NASDAQ: SLSMarket Cap $3.90B
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
SELLAS Life Sciences Group, Inc. most recently reported annual revenue of $0, a net loss of $27.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
SELLAS Life Sciences Group, Inc.: net profit was positive in 0 of 10 reported years; operating margin moved from -893.8% to -4195.0%, a shift of -3301.2 percentage points; the most recent year shows a net loss of $27.0M.
Income Statement — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Revenue
$0
$0
$0
$0
$2.0M
$8.0M
$1.0M
$0
$0
$0
Operating Expenses
$16.0M
$16.0M
$32.0M
$20.0M
$19.0M
$33.0M
$43.0M
$38.0M
$32.0M
$28.0M
Operating Profit
−$16.0M
−$16.0M
−$32.0M
−$20.0M
−$17.0M
−$25.0M
−$42.0M
−$38.0M
−$32.0M
−$28.0M
Operating Margin
—
—
—
—
-893.8%
-332.8%
-4195.0%
—
—
—
Other Income
$5.0M
−$8.0M
$3.0M
$1.0M
$0
$4.0M
$1.0M
$1.0M
$1.0M
$1.0M
Interest
$4.0M
$0
$0
$0
$0
$0
$0
$0
$0
$0
Depreciation
$0
$0
$22.0M
$17.0M
$0
$1.0M
$0
$38.0M
$32.0M
$0
Profit Before Tax
−$18.0M
−$24.0M
−$29.0M
−$19.0M
−$17.0M
−$21.0M
−$41.0M
−$37.0M
−$31.0M
−$27.0M
Tax rate (%)
-1.4%
-1.1%
4.7%
0.4%
0.1%
1.1%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$24.0M
−$24.0M
−$28.0M
−$19.0M
−$17.0M
−$21.0M
−$41.0M
−$37.0M
−$31.0M
−$27.0M
EPS
−$933.13
−$521.91
−$157.72
−$10.92
−$2.11
−$1.34
−$2.13
−$1.34
−$0.50
−$0.25
Quarterly Results — Last 12 Quarters (USD millions)
8 duplicate period labels in the source data were collapsed.
Metric
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$8.0M
$10.0M
$8.0M
$7.0M
$7.0M
$6.0M
$7.0M
$7.0M
$8.0M
$9.0M
$11.0M
$11.0M
Operating Profit
−$8.0M
−$10.0M
−$8.0M
−$7.0M
−$7.0M
−$6.0M
−$7.0M
−$7.0M
−$8.0M
−$9.0M
−$11.0M
−$11.0M
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
−$8.0M
−$10.0M
−$7.0M
−$7.0M
−$7.0M
−$6.0M
−$7.0M
−$7.0M
−$8.0M
−$8.0M
−$10.0M
−$10.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$8.0M
−$10.0M
−$7.0M
−$7.0M
−$7.0M
−$6.0M
−$7.0M
−$7.0M
−$8.0M
−$8.0M
−$10.0M
−$10.0M
EPS
−$0.26
−$0.21
−$0.13
−$0.10
−$0.09
−$0.07
−$0.07
−$0.06
−$0.05
−$0.05
−$0.05
−$0.05
Over the 10 years reported for SELLAS Life Sciences Group, Inc., borrowings decreased from $16.0M in 2016 to $1.0M in 2025, cash stood at $72.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 10.71 times.
Balance Sheet — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
$66.0M
$34.0M
$17.0M
$17.0M
$46.0M
$26.0M
$21.0M
$6.0M
$19.0M
$78.0M
Current Assets
$37.0M
$13.0M
$6.0M
$8.0M
$37.0M
$23.0M
$18.0M
$3.0M
$16.0M
$75.0M
Cash
$18.0M
$2.0M
$5.0M
$7.0M
$35.0M
$21.0M
$17.0M
$3.0M
$14.0M
$72.0M
Inventory
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Receivables
$0
$0
$0
$0
$1.0M
$0
$0
$0
$0
$0
Fixed Assets
$0
$0
$0
$0
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Investments
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Other Assets
$6.0M
$2.0M
$2.0M
$2.0M
$2.0M
$2.0M
$2.0M
$2.0M
$2.0M
$2.0M
Total Liabilities
$37.0M
$31.0M
$12.0M
$11.0M
$18.0M
$6.0M
$16.0M
$14.0M
$10.0M
$7.0M
Current Liabilities
$30.0M
$25.0M
$6.0M
$5.0M
$12.0M
$5.0M
$16.0M
$14.0M
$10.0M
$7.0M
Borrowings
$16.0M
$11.0M
$0
$0
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
Other Liabilities
$21.0M
$20.0M
$12.0M
$10.0M
$17.0M
$5.0M
$15.0M
$13.0M
$9.0M
$6.0M
Equity
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Reserves
$29.0M
$2.0M
$5.0M
$6.0M
$28.0M
$20.0M
$5.0M
−$8.0M
$9.0M
$71.0M
For SELLAS Life Sciences Group, Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $28.0M; free cash flow was positive in 0 of 10 years; financing activities used $1.0M in the latest year, which covers debt repayment, dividends and buybacks.
Cash Flow Statement — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating Cash Flow
−$45.0M
−$11.0M
−$30.0M
−$18.0M
−$10.0M
−$26.0M
−$24.0M
−$31.0M
−$35.0M
−$28.0M
Investing Cash Flow
−$1.0M
$2.0M
$0
$0
$0
$0
−$9.0M
−$11.0M
$0
$0
Financing Cash Flow
$0
$0
$0
$4.0M
$9.0M
$3.0M
$0
$0
$1.0M
−$1.0M
Net Cash Flow
−$12.0M
−$4.0M
−$7.0M
$2.0M
$28.0M
−$14.0M
−$4.0M
−$15.0M
$11.0M
$58.0M
Free Cash Flow
−$45.0M
−$11.0M
−$30.0M
−$18.0M
−$10.0M
−$26.0M
−$28.0M
−$37.0M
−$35.0M
−$28.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
-1.01
EV / EBITDA
-40.22
FCF Yield
-1.68%
Quick Ratio
14.92
Interest Coverage
—
Return 1Y
438.36%
Return 3Y
763.74%
Return 5Y
17.27%
SELLAS Life Sciences Group, Inc. (SLS) financials — frequently asked questions
What is SELLAS Life Sciences Group, Inc.'s annual revenue?
SELLAS Life Sciences Group, Inc. (SLS) reported annual revenue of $0 in its most recent fiscal year.
What is SELLAS Life Sciences Group, Inc.'s net profit?
SELLAS Life Sciences Group, Inc. (SLS) reported a net loss of $27.0M in its most recent fiscal year.
What is SLS EV/EBITDA?
SELLAS Life Sciences Group, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -40.22. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks